| Literature DB >> 25369327 |
Michael E Sutton1, Sanna op den Dries1, Negin Karimian1, Pepijn D Weeder1, Marieke T de Boer2, Janneke Wiersema-Buist3, Annette S H Gouw4, Henri G D Leuvenink3, Ton Lisman1, Robert J Porte2.
Abstract
Although normothermic machine perfusion of donor livers may allow assessment of graft viability prior to transplantation, there are currently no data on what would be a good parameter of graft viability. To determine whether bile production is a suitable biomarker that can be used to discriminate viable from non-viable livers we have studied functional performance as well as biochemical and histological evidence of hepatobiliary injury during ex vivo normothermic machine perfusion of human donor livers. After a median duration of cold storage of 6.5 h, twelve extended criteria human donor livers that were declined for transplantation were ex vivo perfused for 6 h at 37 °C with an oxygenated solution based on red blood cells and plasma, using pressure controlled pulsatile perfusion of the hepatic artery and continuous portal perfusion. During perfusion, two patterns of bile flow were identified: (1) steadily increasing bile production, resulting in a cumulative output of ≥ 30 g after 6 h (high bile output group), and (2) a cumulative bile production <20 g in 6 h (low bile output group). Concentrations of transaminases and potassium in the perfusion fluid were significantly higher in the low bile output group, compared to the high bile output group. Biliary concentrations of bilirubin and bicarbonate were respectively 4 times and 2 times higher in the high bile output group. Livers in the low bile output group displayed more signs of hepatic necrosis and venous congestion, compared to the high bile output group. In conclusion, bile production could be an easily assessable biomarker of hepatic viability during ex vivo machine perfusion of human donor livers. It could potentially be used to identify extended criteria livers that are suitable for transplantation. These ex vivo findings need to be confirmed in a transplant experiment or a clinical trial.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25369327 PMCID: PMC4219693 DOI: 10.1371/journal.pone.0110642
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Biochemical Composition of Perfusion Fluid Used For Normothermic Machine Perfusion of Donor Livers.
|
|
|
|
|
| pH | 7.40 | 7.34–7.45 | 7.35–7.45 |
| pCO2 (kPa) | 4.1 | 3.5–4.6 | 4.6–6.0 |
| pO2 (kPa) | 71 | 65–75 | 9.5–13.5 |
| sO2 (%) | 100 | 99–100 | 96–99 |
| HCO3- (mmol/L) | 19 | 17–21 | 21–25 |
| Base Excess (mmol/L) | −4.6 | −6.7–−3.5 | −3 to 3.0 |
| Na+ (mmol/L) | 150 | 145–154 | 135–145 |
| K+ (mmol/L) | 4.4 | 3.8–5.6 | 3.5–5.0 |
| Free Ca2+ (mmol/L) | 0.67 | 0.61–0.72 | 1.15–1.29 |
| Glucose (mmol/L) | 14 | 13–15 | 4–9 |
| Lactate (mmol/L) | 6 | 6–7 | 0.5–2.2 |
| Hemoglobin (mmol/L) | 4.7 | 4.6–4.9 | 8.7–10.6 |
| Albumin (mmol/L) | 31 | 29–33 | 35–50 |
| Chloride (mmol/L) | 97 | 91–98 | 97–107 |
| Urea (mmol/L) | 3.5 | 2.9–3.6 | 2.5–7.5 |
| Phosphate (mmol/L) | 1.8 | 1.5–2.2 | 0.7–1.5 |
| Magnesium (mmol/L) | 0.55 | 0.51–0.63 | 0.70–1.00 |
| Alanine-aminotransferase (U/L) | 9 | 8–11 | 0–45 |
| Aspartate-aminotransferase (U/L) | 13 | 13–17 | 0–40 |
| Alkaline phosphatase (U/L) | 24 | 23–28 | 0–120 |
| Gamma-glutamyltransferase (U/L) | 9 | 7–16 | 0–40 |
| Lactate dehydrogenase (U/L) | 101 | 93–114 | 0–250 |
| Total bilirubin (µmol/L) | 2 | 2–3 | 0–17 |
* To convert values for glucose to mg/dL, multiply by 18.02. To convert values for lactate to mg/dL, multiply by 9.01. To convert values for hemoglobin to g/dL, multiply by 1.650. To convert the value for bilirubin to mg/dL, divide by 17.1.
Figure 1Cumulative bile production during ex vivo normothermic machine perfusion of human donor livers.
Presented are individual values for 12 livers that were declined for transplantation. Ex vivo machine perfusion and viability testing was started after a median cold storage of 6.5 hours. Two distinct patterns of bile flow could be identified: 1) a steadily increasing bile production, resulting in a cumulative bile output of ≥30 g during the 6 h of perfusion (green lines), and 2) an initially increasing bile production during the first 2–3 hours, followed by a diminishing production, resulting in a cumulative bile production in 6 h <20 g (red lines).
Donor Characteristics.
| Total group | Low Bile Output | High Bile Output | P-value | |
| (n = 12) | (n = 6) | (n = 6) | ||
|
| 0.12 | |||
| DCD | 10 (83%) | 4 (67%) | 6 (100%) | |
| DBD | 2 (17%) | 2 (33%) | 0 (0%) | |
|
| 61 (50–64) | 55 (48–65) | 63 (51–65) | 0.47 |
|
| 0.22 | |||
| Male | 8 (67%) | 3 (50%) | 1 (17%) | |
| Female | 4 (33%) | 3 (50%) | 5 (83%) | |
|
| 1.77 (1.67–1.80) | 1.77 (1.64–1.81) | 1.78 (1.71–1.81) | 0.69 |
|
| 88 (76–98) | 90 (85–100) | 78 (75–95) | 0.20 |
|
| 0.25 | |||
| DCD + age>60 years | 5 (41%) | 1 (17%) | 4 (67%) | |
| DCD + high BMI | 3 (25%) | 2 (33%) | 1 (17%) | |
| DCD + other reason | 2 (17%) | 1 (17%) | 1 (17%) | |
| Severe steatosis | 2 (17%) | 2 (33%) | 0 (0%) | |
|
| 2.35 (2.01–2.54) | 2.48 (2.23–2.61) | 2.20 (1.83–2.42) | 0.35 |
|
| 38 (24–59) | 59 (34–104) | 25 (14–49) | 0.05 |
|
| 90 (39–130) | 111 (62–144) | 65 (30–130) | 0.27 |
|
| 14.0 (12.3–16.3) | 15.0 (14.0–16.8) | 12.9 (9.1–39.7) | 0.20 |
|
| 1.00 | |||
| UW solution | 6 (50%) | 3 (50%) | 3 (50%) | |
| HTK solution | 6 (50%) | 3 (50%) | 3 (50%) | |
|
| 24 (15–52) | 30 (2–53) | 24 (17–53) | 0.27 |
|
| 17 (16–20) | 19 (9–26) | 17 (15–18) | 0.31 |
|
| 43 (33–71) | 51 (27–72) | 43 (34–68) | 0.35 |
|
| 389 (458–585) | 530 (431–750) | 409 (363–473) | 0.11 |
|
| 2.09 (1.60–2.24) | 2.17 (1.60–2.31) | 2.03 (1.71–2.18) | 0.63 |
* One DCD donor with history of iv drug abuse (low bile output group) and one donor with prolonged s02<30% after withdrawal of life support (high bile output group).
** defined as macrovesicular steatosis with more than 60% of hepatocytes involved.
*** last known value before procurement.
Donor warm ischemia times was defined as the time interval between cardiac arrest and start of in situ cold perfusion. Total donor warm ischemia time was defined as the time interval between switch -off and start of in situ cold perfusion.
Continuous variables are presented as median and interquartile range, categorical variables are presented as numbers and percentage.
Abbreviations used: DCD, donation after cardiac death; DBD, donation after brain death; ALT, alanine aminotransferase; GGT, gamma glutamate transferase; UW, university of Wisconsin; HTK, Histidine- tryptophan-ketoglutarate.
Figure 2Changes in portal flow (panel A) and arterial flow (panel B) during ex vivo normothermic machine perfusion of human donor livers, using a pressure controlled device.
Flow in the portal vein and hepatic artery increased rapidly during the first 30 min and flows remained stable thereafter for the entire 6 h perfusion period. There were no significant differences in portal flow and although median arterial flow was constantly lower in livers with a low bile output, compared to the high bile output group, this did not reach statistical significance.
Biochemical Composition of Perfusion Fluid and Bile after 6 hour of Ex Vivo Normothermic Machine Perfusion.
| High Bile Output | Low Bile Output | P- value | |
| (n = 6) | (n = 6) | ||
|
| |||
| pH | 7.36 (7.25–7.40) | 7.34 (7.29–7.40) | 1.00 |
| pCO2 (kPa) | 6.7 (5.9–7.8) | 5.0 (3.4–6.3) | 0.08 |
| pO2(kPa) | 64 (54–65) | 35 (10–67) | 0.42 |
| sO2 (%) | 100 (99–100) | 98 (94–99) |
|
| HCO3 - (mmol/L) | 26 (22–28) | 18 (13–29) | 0.20 |
| Added HCO3 − 8.4% (mL) | 8 (0–20) | 25 (4–86) | 0.24 |
| Base excess (mmol/L) | +0.1 (−3.6–+3.6) | −6.8 (−12.0–−4.0) | 0.34 |
| Hemoglobin (mmol/L) | 4.2 (3.7–4.3) | 4.3 (4.1-4.6) | 0.26 |
| Oxygen consumption | 21 (16–22) | 60 (27–119) | 0.30 |
|
| |||
| Na+ (mmol/L) | 154 (143–155) | 142 (139–151) | 0.26 |
| K+ (mmol/L) | 4 (2–8) | 13 (8–18) |
|
| Urea (mmol/L) | 14 (11–16) | 15 (12–22) | 0.63 |
| Albumin (g/L) | 23 (22–24) | 26 (25–29) |
|
| Glucose (mmol/L) | 10 (8–19) | 23 (16–32) | 0.07 |
| Lactate (mmol/L) | 2 (1–4) | 6 (3–11) |
|
|
| |||
| ALT (U/L) | 2795 (1761–3972) | 11074 (6144–16050) |
|
| ALP (U/L) | 36 (25–44) | 154 (82–258) |
|
| GGT (U/L) | 35 (20–55) | 124 (107–187) | 0.06 |
| LDH (U/L) | 6227 (5151–6703) | 22119 (9584–34558) | 0.06 |
| Total bilirubin (µmol/L) | 3 (3–3) | 5 (3–7) | 0.20 |
|
| |||
| Biliary pH | 7.58 (7.56–7.70) | 7.37 (7.05–7.71) | 0.10 |
| Biliary HCO3 − (mmol/L) | 44 (35–50) | 20 (7–41) | 0.09 |
| Bilirubin in bile (µmol/L) | 1100 (968–1398) | 270 (215–525) |
|
* To convert values for glucose to mg/dL, multiply by 18.02. To convert values for lactate to mg/dL, multiply by 9.01. To convert values for hemoglobin to g/dL, multiply by 1.650. To convert the value for bilirubin to mg/dL, divide by 17.1. To convert kPa to mmHg, multiply by 7.5.
** Peak values during 6 h of machine perfusion.
Abbreviations used: ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamate transferase; LDH, lactate dehydrogenase.
Figure 3Changes in hepatic energy content as reflected by hepatic ATP content.
In contrast to livers with low bile output, livers in the high bile output group showed a significantly higher hepatic ATP content during the course of NMP. (AUC p = 0.04).
Figure 4Histology of livers after 6 hours of normothermic machine perfusion.
In comparison to livers with high bile output, livers in the low bile output group displayed more signs of hepatic necrosis (panels A and B) and venous congestion (panels C en D). Despite these differences in hepatic parenchymal damage between the two groups, there were no major differences in the degree of biliary damage (panels E and F).
Criteria to Assess Bile Production after 2.5 hours of Normothermic Machine Perfusion.
| Liver (Number) | Cumulative Bile Output After 2.5 h (g) | Bile Output Between 1.5 h and 2.5 h (g) | Meets Both Criteria | |
|
| ||||
| 1 | 6.54 | 2.52 | No | |
| 2 | 12.53 | 3.14 | No | |
| 3 | 1.86 | 0.37 | No | |
| 4 | 4.66 | 2.19 | No | |
| 5 | 0.00 | 0.00 | No | |
| 6 | 8.14 | 2.36 | No | |
|
| ||||
| 7 | 18.77 | 7.22 | Yes | |
| 8 | 12.93 | 7.33 | Yes | |
| 9 | 14.92 | 8.50 | Yes | |
| 10 | 10.55 | 5.00 | Yes | |
| 11 | 15.72 | 4.66 | Yes | |
| 12 | 25.35 | 8.85 | Yes |
Criteria are: 1) Cumulative bile production of ≥10 grams after 2.5 h and 2) a bile production of ≥4 grams in the preceding hour (1.5–2.5 h of perfusion).